Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro
- PMID: 11205250
Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro
Abstract
The cyanoguanidine CHS 828 was recently shown to possess potent anti-tumour effects both in vitro and in vivo. The exact mechanism of action of CHS 828 is not known, but recent results have indicated that induction of programmed cell death may be one mechanism by which CHS 828 exerts its anti-tumour effects. To investigate this aspect in more detail, we studied the effect of CHS 828 and the reference compound Taxol beta on programmed cell death in human breast cancer cells in vitro. Both compounds were found to induce DNA fragmentation in the cells. However, microscopic examination of the cells demonstrated that CHS 828 and Taxol triggered different types of cell death. In the CHS 828-treated cultures most cells were found to be Annexin-V positive, indicating that these cells were early apoptotic cells, while no morphological characteristics of classical apoptosis were seen. In contrast, the cells in the Taxol-treated cultures displayed morphological features characteristic of classical apoptotic cells, but no Annexin-V positive cells could be observed. These findings together with the previously reported potent effects of CHS 828 on tumour cells, makes CHS 828 a promising new agent for the treatment of cancer patients.
Similar articles
-
CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.Cancer Res. 1999 Nov 15;59(22):5751-7. Cancer Res. 1999. PMID: 10582695
-
Activation of p53 protein in normal and in tumor cells by a novel anticancer agent CHS 828.Drugs Exp Clin Res. 2003;29(2):53-67. Drugs Exp Clin Res. 2003. PMID: 12951835
-
Antitumor activity of paclitaxel (taxol) analogues on MDR-positive human cancer cells.Anticancer Drug Des. 1998 Jul;13(5):489-99. Anticancer Drug Des. 1998. PMID: 9702212
-
Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy.Leuk Res. 2004 Jul;28(7):667-71. doi: 10.1016/j.leukres.2003.10.008. Leuk Res. 2004. PMID: 15158086 Review.
-
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.Biochem Pharmacol. 2001 May 15;61(10):1183-93. doi: 10.1016/s0006-2952(01)00570-6. Biochem Pharmacol. 2001. PMID: 11322922 Review.
Cited by
-
The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro--from cytotoxic synergy to complete inhibition of apoptosis.Br J Pharmacol. 2002 Oct;137(4):568-73. doi: 10.1038/sj.bjp.0704888. Br J Pharmacol. 2002. PMID: 12359640 Free PMC article.
-
NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance.Front Oncol. 2019 May 2;9:292. doi: 10.3389/fonc.2019.00292. eCollection 2019. Front Oncol. 2019. PMID: 31119097 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical